Real-time fMRI Neurofeedback in Patients With MCI

NCT ID: NCT04020744

Last Updated: 2024-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Increased activity in the hippocampus (i.e., hyperactivity) during a fMRI memory task was found in patients with Mild Cognitive Impairment due to Alzheimer's disease (MCI). Those with increased hippocampal activity exhibited elevated clinical progression. Reducing hippocampal hyperactivity with pharmacological treatment reduced hyperactivity and improved memory performance. The investigators of this study will test whether real-time fMRI neurofeedback will also downregulate hippocampal activity and thereby improve memory performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's disease (AD) is an insidious and progressive neurodegenerative disorder accompanied by extracellular deposits of beta-amyloid ( aβ) and the increase of cognitive dysfunctions. Several functional magnet resonance imaging (fMRI) studies in the prodromal stage of AD (i.e., in MCI) have found increased hippocampal activity during a memory task to be predictive of memory worsening and disease progression. In this study the investigators are aiming to reduce hippocampal hyperactivity with real-time fMRI neurofeedback and test whether this will improve memory performance.

This study will use a randomized, single-blind, parallel group design. Patients with MCI and healthy participants will be assigned to receive feedback from either the hippocampus (experimental group, N=42) or from another brain area (alternate ROI feedback group, N=42). All participants will be instructed to downregulate activity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
For blinding of the participants, they will be told that they will be asked to regulate one of two brain regions, without mentioning the specific area.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy elderly participants receiving feedback from the hippocampus

This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.

Group Type ACTIVE_COMPARATOR

real-time fMRI based neurofeedback from the hippocampus

Intervention Type OTHER

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

healthy elderly participants receiving feedback from another area

This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.

Group Type SHAM_COMPARATOR

real-time fMRI based neurofeedback from another brain area

Intervention Type OTHER

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

patients with MCI receiving feedback from the hippocampus

This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.

Group Type EXPERIMENTAL

real-time fMRI based neurofeedback from the hippocampus

Intervention Type OTHER

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

patients with MCI receiving feedback from another brain area

This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.

Group Type SHAM_COMPARATOR

real-time fMRI based neurofeedback from another brain area

Intervention Type OTHER

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

real-time fMRI based neurofeedback from the hippocampus

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

Intervention Type OTHER

real-time fMRI based neurofeedback from another brain area

During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intact activities of daily living
* Fluent in German
* Normal/corrected-to-normal vision
* Written informed consent

Exclusion Criteria

* Dementia
* Current/lifetime severe psychiatric or neurological disorder
* History of seizures
* Psychotropic medication
* Currently/lifetime drug or alcohol abuse
* Brain damage
* Magnetisable implants
Minimum Eligible Age

60 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role collaborator

University of Bern

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jessica Peter, PD Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Bern

Stefan Klöppel, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Bern

Frank Scharnowski, Prof. Dr.

Role: STUDY_CHAIR

University of Vienna

Roland Wiest, Prof. Dr.

Role: STUDY_CHAIR

University of Bern

Katharina Klink

Role: STUDY_CHAIR

University of Bern

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SITEM (Swiss Institute for Translational and Entrepreneurial Medicine)

Bern, , Switzerland

Site Status

University of Zurich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Klink K, Jaun U, Federspiel A, Wunderlin M, Teunissen CE, Kiefer C, Wiest R, Scharnowski F, Sladky R, Haugg A, Hellrung L, Peter J. Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment. BMC Psychiatry. 2021 Feb 9;21(1):87. doi: 10.1186/s12888-021-03091-8.

Reference Type DERIVED
PMID: 33563242 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1163

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.